| Bioactivity | FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties[1]. | ||||||||||||
| Target | Somatostatin release | ||||||||||||
| Invitro | FK962 (1 nM-1 μM) significantly enhances high K+-evoked somatostatin release from rat hippocampal slices. FK962 also significantly reduces somatostatin-induced inhibition of Ca2+ channels at 1-100 nM in single rat hippocampal neurons using whole-cell patch-clamp[1]. | ||||||||||||
| In Vivo | FK962 (0.1, 0.3 or 1.0 mg/kg; i.p.) and Donepezil (a single dose of 1 mg/kg) act synergistically to improve cognition in rats: as an add-on therapy for Alzheimer's disease[2]. Animal Model: | ||||||||||||
| Name | FK962 | ||||||||||||
| CAS | 283167-06-6 | ||||||||||||
| Formula | C14H17FN2O2 | ||||||||||||
| Molar Mass | 264.30 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Tokita K, et al. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol. 2005 Dec 19;527(1-3):111-20. [2]. McCarthy AD, et al. FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease. Pharmacol Biochem Behav. 2011 Mar;98(1):76-80. |